Biopharmaceutical company GSK plc (LSE/NYSE:GSK) confirmed on Tuesday that it is appealing a Delaware court decision allowing plaintiff expert testimony in the ongoing Zantac (ranitidine) litigation.
The company argues that the ruling contradicts how the Daubert standard is typically applied and could impact all Delaware businesses.
GSK, joined by Pfizer (NYSE:PFE), Sanofi (Euronext Paris:SAN) (Nasdaq:SNY) and Boehringer Ingelheim, has filed with the Delaware Supreme Court seeking to overturn the lower court's decision. GSK maintains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
A decision on whether to grant interlocutory review and hear the appeal is expected later this year.
Chroma Medicine names new director
Medivir to present promising Fostrox data for liver lancer at ESMO Congress
TME Pharma to present NOX-a12 glioblastoma trial results at ESMO Congress 2024
Full-Life Technologies signs licence agreement with SK Biopharmaceuticals
Hoth Therapeutics adds three centres to clinical trial for cancer patients
SFA Therapeutics names new chief operating officer
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation